Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.89 USD
+0.04 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.88 -0.01 (-0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.89 USD
+0.04 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.88 -0.01 (-0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Omega Therapeutics (OMGA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Allogene (ALLO) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
by Zacks Equity Research
Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of 14.29% and 21.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
How Allogene (ALLO) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
by Zacks Equity Research
Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics
by Zacks Equity Research
Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
by Zacks Equity Research
Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
by Zacks Equity Research
Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.
Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug
by Zacks Equity Research
Data from an early-stage study shows that treatment with Karuna's (KRTX) KarXT was not associated with clinically meaningful increases in blood pressure in schizophrenia patients.
Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.
Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
by Zacks Equity Research
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
by Zacks Equity Research
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.
CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.